Bluejay Diagnostics, Inc. Net Fee Amt
Bluejay Diagnostics, Inc. (BJDX) had Net Fee Amt of $83.69 as of 2026-08-12, per its S-8 filed 2026-08-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-12
- 2026-08-12: Net Fee Amt $83.69.
- 2026-06-15: Net Fee Amt $6.92K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-12 | $83.69 S-8 · filed 2026-08-12 |
| 2026-06-15 | $6.92K S-3 · filed 2026-06-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |